Participating Companies

Abide Tx
Serine hy­dro­lase-tar­get­ed ther­a­peu­tics har­ness­ing the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal and pain di­s­or­ders w. limit­ed or no treat­ment op­tions. Ph 2: Tourette Syn­drome on­go­ing with da­ta... [more in­for­ma­tion]
Acceleron Pharma Inc [XLRN] US$1,936 MM MCap
De­vel­op­ing TGF-be­ta ther­a­peu­tics to treat se­ri­ous and rare dis­eas­es. Lead ther­a­peu­tic can­di­date in he­ma­tol­o­gy, lus­pa­ter­cept, un­der a glob­al part­n­er­ship with Cel­gene, re­port­ed pos­i­tive Phase 3 ME­DAL­IST... [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$154 MM MCap
U.S. launch of DSU­VIA (sufen­tanil sublin­gual tablet 30 mcg) exp. 1Q19. Re­cent­ly ap­proved for mgmt of acute pain se­vere enough to re­quire opi­oid anal­gesic (adult pa­tients in cer­ti­fied med­i­cal­ly... [more in­for­ma­tion]
Adamas Pharmaceuticals, Inc. [ADMS] US$244 MM MCap
Launched GO­COV­RI™ for LID in pa­tients w/ Parkin­son’s dis­ease. Late-stage pipe­line in­cludes ADS-5102 in P3 for MS walk­ing im­pair­ment and ADS-4101, high-dose, mod­i­fied re­lease la­cosamide, which... [more in­for­ma­tion]
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. 4 clin­i­cal / late-stage, pro­pri­e­tary pro­grams in­clud­ing pso­ri­a­sis, B-cell au­toim­mune dis­eas­es, & liv­er dis­eas­es. Pipe­line al­so in­cludes Dx... [more in­for­ma­tion]
Affimed N.V. [AFMD] US$222 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal with Ge­nen­tech ($96M up­front / $5B po­ten­tial) to de­vel­op NK-cell en­gager-based ther­a­peu­tics through... [more in­for­ma­tion]
Allele Biotechnology
​Lead­ing in­de­pen­dent Nanoanti­boy (nAb) tech plat­form. Mul­ti­ple whol­ly-owned hu­man­ized nAb ther­a­peu­tics in late-stage pre-clin­i­cal studies. Shares the sci­en­tif­ic foun­da­tion Ab­l­ynx used to de­vel­op its... [more in­for­ma­tion]
Amarin Corporation [AMRN] US$5,632 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from... [more in­for­ma­tion]
Ph3 ready hor­mone ther­a­py com­pany with an in­jectable, long-act­ing GnRH an­ta­g­on­ist for pros­tate can­cer and be­nign pro­stat­ic hy­per­pla­sia. An in­jectable en­ables ex­tend­ed drug ac­tiv­i­ty, which is im­por­tant... [more in­for­ma­tion]
De­vel­op­ing APX005: hu­man­ized mAb CD40 ag­on­ist. 3 in­ter­nal­ly de­vel­oped pro­grams (1 Ph 2, 2 PC pro­grams) and 8 part­nered pro­grams (1 Ph 3, 2 Ph 2, 3 Ph 1, vari­ous PC). Dose-es­ca­la­tion study in pts w... [more in­for­ma­tion]
Aptorum Group [APM] US$457 MM MCap
Ap­to­rum Group is a Hong Kong-based life sci­ence and bio­phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to ac­quir­ing, de­vel­op­ing and com­mer­cial­iz­ing nov­el bio­phar­ma­ceu­ti­cal prod­ucts and in­no­va­tions around the world. [more in­for­ma­tion]
Arcus Biosciences [RCUS] US$452 MM MCap
Ar­cus Bio­s­ciences is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on cre­at­ing in­no­va­tive can­cer im­munother­a­pies. Ar­cus has sev­er­al pro­grams tar­get­ing im­por­tant im­muno-on­col­o­gy path­ways,... [more in­for­ma­tion]
AsclepiX Therapeutics
Oph­thal­mol­o­gy fo­cus; tech­nol­o­gy out of Johns Hop­kins. Plan­n­ing 4Q19 IND and 1Q20 Ph1/2 ini­ti­a­tion (DME and Wet AMD). AX­T107: nov­el pep­tide in­hibit­ing VEGF and ac­ti­vat­ing Tie2; de­mon­s­trat­ed ef­fi­ca­cy... [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung... [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$541 MM MCap
Nov­el, oral, live bio­ther­a­peu­tics ad­dress­ing dis­eas­es as­soc w mi­cro­biome. HBV pro­gram ad­vanc­ing mul­ti­ple drug can­di­dates; ful­ly in­te­grat­ed mi­cro­biome plat­form in­cludes ro­bust strain ID and se­lec­tion... [more in­for­ma­tion]
Aurinia Pharmaceuticals, Inc. [AUPH] US$635 MM MCap
De­vel­op­ing vo­clos­porin ad­dress­ing lu­pus nephri­tis (LN), fo­cal seg­men­tal glomeru­los­cle­ro­sis (FS­GS) & dry eye syn­drome (DES). - Dry eye top-line da­ta: ear­ly Q1 19 - LN top line da­ta: late Q4 19 - FS­GS... [more in­for­ma­tion]
Avacta [AVCT:LN] £43 MM MCap
De­vel­ops next-gen bi­o­log­ics us­ing its pro­pri­e­tary Af­fimer® plat­form tech­nol­o­gy. It is based on a na­t­u­ral­ly oc­cur­ring hu­man pro­tein, en­gi­neered to be­have like an anti­body, but small­er, sim­pler, more... [more in­for­ma­tion]
AxoGen [AXGN] US$594 MM MCap
Rev gen­er­at­ing; ad­dress­ing pe­ripher­al nerve re­pair w port­fo­lio of re­gen­er­a­tive medicine prod­ucts in US, Ca­na­da et al. Prod­ucts in­cl. Avance Nerve Graft: off-the-shelf com­mer­cial­ly avail pro­cessed... [more in­for­ma­tion]
Ayala Pharma
Tar­get­ed ther­a­pies for on­co in­di­ca­tions w ac­ti­vat­ed Notch path­way (vali­dat­ed in pro­lif­er­a­tion, stem­ness, an­gio­ge­n­e­sis & me­tas­ta­sis; over­ex­pressed in cer­tain ACC, TN­BC & he­ma. can­cers). Lead as­set in... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$147 MM MCap
Molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­ables phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram: Ph2 for ri­vo-cel (al­pha/be­ta ad­d­back T-cell... [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,466 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) n four com­pany-spon­sored trials. Stage 2 of Ph 2 com­bi­na­tion trial with... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$1,638 MM MCap
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
BioPharmX [BPMX] US$25 MM MCap
De­vel­op­ing BPX-04 for rosacea, us­ing pro­pri­e­ta­ty hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. En­rolling Ph2b w da­ta exp in 2019. Com­plet­ed Ph 2b with BPX-01 in acne. [more in­for­ma­tion]
New­ly in­cor­po­rat­ed (Nov 2018), whol­ly owned sub­si­diary of Bio­haven Phar­ma­ceu­ti­cals. Shang­hai-based, led by ex-BMY ex­ec and Bio­haven’s Chief of Corp Strat­e­gy & BD, Don­nie Mc­Grath, Bioshin aims to... [more in­for­ma­tion]
BioTime, Inc [BTX] US$129 MM MCap
Lead (Ph 2) cell re­place­ment can­di­date: OpRe­gen®, reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py: Dry AMD. Lead cell de­liv­ery clin­i­cal pro­gram: Rene­via®: med de­vice de­vel­oped as al­ter­na­tive to... [more in­for­ma­tion]
BlinkBio, Inc.
Blink­Bio has in­no­vat­ed Tun­able Drug Con­ju­gates (TDCs), a new gen­er­a­tion of Drug Con­ju­gate ther­a­pies de­signed to im­prove on the safe­ty and ef­fi­ca­cy of con­tem­po­rary Anti­body Drug Con­ju­gates (ADCs) –... [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] US$72 MM MCap
NurOwn® au­tol­o­gous cell ther­a­py plat­form for neu­rode­gen­er­a­tive dis­eas­es. Lead can­di­date for ALS, Ph2 eval­u­at­ed 60 ALS pts w fa­vor­able safe­ty/tol­er­a­bil­i­ty. Ph3 cur­rent­ly en­rolling 200 pts across 6 US... [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr2,433 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing in­no­va­tive/long-act­ing medicines for se­vere & chron­ic con­di­tions (e.g. opi­oid de­pen­dence, pain, can­cer & en­docrine di­s­or­ders). Fluid­Crys­tal® drug de­liv­ery tech­nolo­gies for... [more in­for­ma­tion]
Caris Life Sciences
Pre­ci­sion medicine com­pany uti­l­iz­ing pro­pri­e­tary plat­forms to pro­vide on­col­o­gists with ac­tion­able treat­ment da­ta for can­cer and other com­plex dis­eas­es. Caris Molec­u­lar In­tel­li­gence® (CMI), is... [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$356 MM MCap
Re­ceived MN­PA (f.k.a. CF­DA) ap­pro­val for EVOMELA® (mel­pha­lan for in­jec­tion: mul­ti­ple myelo­ma) on Dec 3, 2018; CF­DA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum Phar­ma). [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$268 MM MCap
Fir­dapse ap­proved in Nov 2018 for Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) - 2 pos­i­tive Ph 3s com­plete, po­ten­tial launch ear­ly '19. Ad­dl on­go­ing trials in con­geni­tal myas­thenic syn­dromes (CMS), MuSK... [more in­for­ma­tion]
CellMax Life
Pri­vate liquid biop­sy com­pany ded­i­cat­ed to trans­form­ing how can­cer is de­tect­ed and ma­n­aged with glob­al­ly af­ford­able non-in­va­sive blood tests for ear­ly can­cer de­tec­tion and mon­i­tor­ing. Cell­Max Life’s... [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$370 MM MCap
Cel­lu­lar Biomedicine Group (NAS­DAQ: CB­MG), a clin­i­cal-stage bio­phar­ma, will bring the first mar­ket­ed CAR-T cell ther­a­py, Kym­ri­ah, to Chi­na (the se­cond largest health­care mar­ket) with its strate­g­ic... [more in­for­ma­tion]
Context Therapeutics
Con­text Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to cre­at­ing new medicines to treat hor­mone-re­spon­sive can­cers. Con­text’s lead pro­gram is Apris­tor®, an in­vesti­ga­tio­n­al... [more in­for­ma­tion]
CTI BioPharma [CTIC] US$72 MM MCap
Lead can­di­date pa­cri­tinib, oral ki­nase in­hibi­tor w spe­ci­fic­i­ty for JAK2, FLT3, IRAK1, and CS­F1R in Ph 2 for treat­ment of myelo­fi­bro­sis. Up­com­ing ca­t­alysts: CHMP opinion Q1'19, com­plete en­roll­ment in... [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). Na­t­u­ral­ly se­quenced, op­ti­mized mR­NA. In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1... [more in­for­ma­tion]
Next-gen NK Cell ther­a­py; en­ter­ing Ph 2 trials in 1H19 (AML HSCT tran­s­plant) with RMAT po­ten­tial in 2H20. Ph 1/2 de­mon­s­trat­ed sig­nif re­duc­tion in re­lapse rates (MD An­der­son). Pos­i­tive pre-IND... [more in­for­ma­tion]
DBV Technologies [DBVT] US$438 MM MCap
DBV Tech­nolo­gies is de­vel­op­ing Vi­askin®, a pro­pri­e­tary tech­nol­o­gy plat­form with broad po­ten­tial ap­pli­ca­tions in im­munother­a­py. Vi­askin is based on epi­cu­ta­neous im­munother­a­py, or EPIT®, DBV’s... [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$172 MM MCap
$100m revs in F18. Pi­oneer in molec­u­lar di­ag­nos­tics (Dx), lead­ing con­ver­gence of clin­i­cal lab­o­ra­to­ries, life sci­ences and IP through de­vt of unique Dx plat­form tech­nolo­gies pro­vid­ing nu­mer­ous... [more in­for­ma­tion]
Epigenomics AG [EPGNY] US$69 MM MCap
Blood-based can­cer de­tec­tion com­pany with DNA methy­la­tion bio­mark­er tech­nol­o­gy. De­vel­ops/com­mer­cial­izes Dx prod­ucts across mul­ti­ple can­cer in­di­ca­tions w/high med­i­cal need. Lead, Epi pro­Colon:... [more in­for­ma­tion]
Erytech Pharma SA [ERYP] US$139 MM MCap
RBC ther­a­peu­tics; ERY­CAPS: hy­po­ton­ic load­ing of ac­tive agents (e.g. en­zymes, anti­genic pep­tides) in al­lo­gene­ic matched donor red blood cells sourced from blood banks. Clin pro­grams ad­dress­ing solid... [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$24 MM MCap
Sm molecule drugs: cas­tra­tion-re­sis­tant pros­tate can­cer. EPI-506, exp to en­ter clin­ic YE19 (se­cond-gen com­pound). De­vel­op­ing com­pounds bind­ing to N-ter­mi­nus of AR and block sig­nal­ing. MOA po­ten­tial­ly... [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$101 MM MCap
Am­pho­ra: Mul­ti­pur­pose Vag­i­nal pH Reg­u­la­tor (MVP-R) be­ing de­vel­oped as a non-hor­mo­n­al, on-de­mand, wo­m­an-con­trolled con­tra­cep­tive vag­i­nal gel; cur­rent­ly com­plet­ing con­fir­ma­to­ry Ph 3 in 1400 wo­m­en in US. [more in­for­ma­tion]
Pro­tein en­gi­neer­ing plat­forms /de­sign high­ly ac­tive & se­lec­tive in­hibi­tors of TGF-Be­ta and EGFR path­ways for on­co and fi­brot­ic dis­eas­es. YM Bio­s­cience spin-out (ac­quired by GILD). Ilia Tikhomirov,... [more in­for­ma­tion]
Genfit SA [GNFTF] US$637 MM MCap
Lead pro­gram Ela­fi­branor is PPAR al­pha/del­ta ag­on­ist in Ph 3 for NASH and Ph 2 for PBC. Ful­ly en­rolled in Ph 3 RE­SOLVE-IT trial for NASH w da­ta exp YE 2019. Ph 2 PBC da­ta exp YE 2018. On­go­ing NASH... [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €73 MM MCap
Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Lead, GS010, Ph 3 for Le­ber Hered­i­tary Op­tic Neu­ro­pa­thy (LHON). RE­V­ERSE Ph 3 to­p­line da­ta an­nounced Apr 2018, RES­CUE Ph... [more in­for­ma­tion]
GW Pharmaceuticals PLC [GWPH] US$4,108 MM MCap
GW is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on dis­cov­er­ing, de­vel­op­ing and com­mer­cial­iz­ing nov­el ther­a­peu­tics from its pro­pri­e­tary cann­abi­noid prod­uct plat­form in a broad range of dis­ease ar­eas. GW,... [more in­for­ma­tion]
I-O; nov­el tgts in Mul­ti­ple Myelo­ma (col­lab w Take­da). Kap­paMab (MM) Ph 2b, da­ta 1H20. Kap­paMab Car-T en­ter­ing clin­ic 2019. Kap­paMab & Lamb­daMab tar­get cell sur­face pro­teins KMA and LMA on ab­nor­mal... [more in­for­ma­tion]
Hua Medicine [2552:HK]
Hua Medicine is a clin­i­cal stage drug de­vel­op­ment com­pany cur­rent­ly fo­cused on de­vel­op­ing a glob­al first-in-class oral drug, Dorza­gli­atin or HM­S5552, for the treat­ment of Type 2 Di­a­betes (T2D). [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$2,929 MM MCap
Chi-Med's pipe­line has eight nov­el late stage on­col­o­gy can­di­dates with six Phase 3 trials and 20+ Phase 1b/2 trials cur­rent­ly un­der­way that are fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. [more in­for­ma­tion]
I-Mab Biopharma
I-Mab Bio­phar­ma is a Chi­na based bio­phar­ma­ceu­ti­cal with fo­cus on de­vel­op­ing in­no­va­tive bi­o­log­ics in the ar­eas of im­muno-on­col­o­gy and au­toim­mune dis­ease for the glob­al mar­kets, in­clud­ing Chi­na; The... [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$80 MM MCap
Lead can­di­date IMO-2125 (TLR 9 ag­on­ist) used in comb w Ipi in PD1 re­frac­to­ry me­lano­ma pts. Ph 3 planned 1Q18; en­rolling ad­dl pts in Ph 2 ex­pan­sion. Com­bo of ipi and IMO-2125 ap­pears to ac­ti­vate im­mune... [more in­for­ma­tion]
ImmuneSensor, LLC
De­vel­op­ing nov­el medicines that tar­get the cGAS (cyclic GMP-AMP syn­thase) - ST­ING (sti­m­u­la­tor of in­ter­fer­on genes) path­way of the in­nate im­mune sys­tem to treat can­cer and au­toim­mune dis­eas­es. The... [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$1,153 MM MCap
Com­mer­cial­iz­ing a ther­a­py uti­l­iz­ing large num­bers of ac­tive T cells to at­tack solid tu­mors, pro­vid­ing a mean­ing­ful clin­i­cal re­sponse in dis­ease ar­eas and pa­tient pop­u­la­tions where other ap­proach­es are... [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$275 MM MCap
Late-stage biotech de­vel­op­ing small molecules and bi­o­log­ics; fo­cused on in­flam­ma­tion, fi­bro­sis and I-O. Lead can­di­date KD025 is a ROCK2 in­hibi­tor in a reg­is­tra­tion trial cGVHD. Plat­form of ROCK... [more in­for­ma­tion]
Marker Therapeutics [MRKR] US$267 MM MCap
A clin­i­cal-stage im­muno-on­col­o­gy com­pany with the po­ten­tial to sig­ni­f­i­cant­ly dis­rupt the cur­rent cell ther­a­py land­s­cape. The Com­pany is de­vel­op­ing a port­fo­lio of non-ge­net­i­cal­ly mod­i­fied,... [more in­for­ma­tion]
Medigene AG [MDG1:DB] €221 MM MCap
Lead­er in T Cell im­munol­o­gy. TCR tar­get­ing PRAME (AML, MDS, MM) en­tered clin­ic March 2018. CTA sub­mitt­ed for TCR tar­get­ing MAGE-A1 (MM, liv­er, and lung can­cer); sev­er­al add'l undis­closed tar­gets &... [more in­for­ma­tion]
Medivir AB [MVIR.B-SE]
Late stage broad pipe­line: remeti­no­s­tat, Ph 3 ready top­i­cal HDAC in­hibi­tor for ear­ly-stage cu­ta­neous T-cell lym­pho­ma; MIV-711, cathepsin K in­hibi­tor for OA, Ph 2 da­ta showed dis­ease mod­i­fy­ing ef­fect... [more in­for­ma­tion]
MEI Pharma, Inc. [MEIP] US$198 MM MCap
4 clin-stage can­di­dates, in­cl 1 in on­go­ing glob­al reg­is­tra­tion trial (pra­ci­no­s­tat), another (ME-401) en­ter­ing Ph 2; in­tends to sub­mit to FDA to sup­port ac­cel­er­at­ed ap­pro­val mar­ket­ing ap­pli­ca­tion. [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$278 MM MCap
Ph 3 trial w/rolu­peri­done tar­get­ing neg­a­tive symp­toms as­soc w/ schi­zophre­nia; du­al MOA (5-HT2A & Sig­ma2 an­ta­g­on­ist); top-line da­ta 1H19. 3 Ph 2b trials on­go­ing w/ sel­torex­ant, in­clud­ing two in MDD and... [more in­for­ma­tion]
Modus Therapeutics AB
Mo­dus Ther­a­peu­tics is a Swedish-based biotech­nol­o­gy com­pany ded­i­cat­ed to de­vel­op­ing ther­a­pies that im­prove blood flow and oxy­gen tran­s­port. The com­pany’s lead pro­ject, se­vu­parin, is cur­rent­ly in an... [more in­for­ma­tion]
MolMed [MLM:MI] €124 MM MCap
Du­al busi­ness mod­el, in­cl R&D on pro­pri­e­tary on­co and on­co-he­ma­tol­o­gy prod­ucts, and third par­ties GMP de­vt and man­u­fac­tur­ing ser­vices. Owns one of the first au­tho­rized cel­lu­lar ther­a­pies (Zal­moxis®,... [more in­for­ma­tion]
Motif Bio plc [MTFB] US$148 MM MCap
PD­U­FA date: Feb 13, 2019 for Antibi­ot­ic Iclaprim. Two Phase 3 trials in pts w acute bac­te­rial skin and skin struc­ture in­fec­tions (ABSS­SI) achieved pri­mary and se­condary end­points. Com­pared to SoC... [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €227 MM MCap
Nano­par­ti­cle-based ra­dio-en­hancer NBTXR3 for soft tis­sue sar­co­ma, head and neck, liv­er, pros­tate, rec­tal and other can­cers. Al­so de­vel­oped for in si­tu vax in comb w I/O ap­proach­es. NanoXray tech­nol­o­gy... [more in­for­ma­tion]
The blurb: NPXe is a phase III phar­ma­ceu­ti­cal and drug de­liv­ery de­vice com­pany which is de­vel­op­ing XENEXTM (xenon gas for in­ha­la­tion) for post car­di­ac ar­rest syn­drome. [more in­for­ma­tion]
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for... [more in­for­ma­tion]
NexImmune, Inc.
Pri­vate IO com­pany de­vel­op­ing unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing... [more in­for­ma­tion]
Oncimmune [ONC:LN] £66 MM MCap
Plat­form bio­mark­er com­pany with pro­pri­e­tary Ear­ly­CDT® tech­nol­o­gy. De­vel­op­ing and com­mer­cial­is­ing au­toanti­body (AAb) tests that can en­able de­tec­tion 4 years or more be­fore stan­dard clin­i­cal di­ag­no­sis,... [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr5,732 MM MCap
De­vel­op­ing Melflufen (Yga­lo): alky­lat­ing pep­tide in class of Pep­ti­dase En­hanced Com­pounds tar­get­ing MM trans­for­ma­tion pro­cess, se­lec­tive­ly tar­gets MM. MoA over­comes re­sis­tance mech­anisms for cur­rent... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A), an epi­ge­net­ic hi­s­tone mod­i­fy­ing en­zyme. Lead CNS com­pound... [more in­for­ma­tion]
Oventus Medical
Aus­tralian-based, med de­vice co estd in 2012 to meet un­met needs of Ob­struc­tive Sleep Ap­ne­ics. In 2013, worked with the CSIRO to de­vel­op pa­tent­ed 3D print­ed air­way tech­nol­o­gy clin­i­cal­ly proven to... [more in­for­ma­tion]
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US fil­ing exp by part­n­er Cos­mo... [more in­for­ma­tion]
Perrigo Company [PRGO] US$6,224 MM MCap
Per­ri­go Com­pany plc, head­quar­tered in Ire­land, has grown to be­come a lead­ing glob­al health­care sup­pli­er. Per­ri­go de­vel­ops, man­u­fac­tures and dis­tributes over-the-coun­ter (OTC) and gener­ic pre­scrip­tion... [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
1H18 to­tal rev­enues of &eu­ro;107M. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized w di­rect sales-force in EU and part­n­er­ship in US w Janssen. Zep­syre in Ph 3 trials for SCLC - da­ta due... [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €497 MM MCap
RU­CON­EST (rhC1INH) mar­ket­ed to treat acute Hered­i­tary An­gioede­ma (HAE) at­tacks with 100% re­sponse rate, no re­lapse, side ef­fects, or plas­ma risk. Sub­mitt­ed sBLA to FDA for pro­phy­laxis of HAE (re­cent... [more in­for­ma­tion]
Phar­varis is a pre­clin­i­cal stage com­pany fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc. [PHAS] US$96 MM MCap
De­vel­op­ing ther­a­pies for treat­ment of or­phan dis­eas­es; ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. Lead can­di­date PB2452, in Ph 1 as a re­v­er­sal agent for an­ti­platelet ther­a­py tica­grelor. Al­so... [more in­for­ma­tion]
Phosphagenics [PPGNY] US$1 MM MCap
Sol­u­bil­i­sa­tion / drug de­liv­ery tech­nol­o­gy TPM (Tar­get­ed Pen­e­tra­tion Ma­trix) com­bines mul­ti­ple forms of Vi­ta­min E. Plat­form en­hances us­a­bil­i­ty char­ac­teris­tics for in­jecta­bles, patch and gel prod­ucts. [more in­for­ma­tion]
Photocure ASA
Rev­enue gen­er­at­ing com­mer­cial stage com­pany fo­cused on urol­o­gy, with lead prod­uct Hexvix/Cysview on mar­ket; op­ti­cal imag­ing agent for im­proved de­tec­tion, re­duced dis­ease re­cur­rence and pro­gres­sion... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$146 MM MCap
Plat­form tech­nol­o­gy com­pany de­vel­op­ing An­ti­calins (en­gi­neered lipo­calin pro­teins) for on­col­o­gy and re­s­pi­ra­to­ry dis­eas­es. 2H18 Phase 1 da­ta for: 1) ful­ly-pro­pri­e­tary IO pro­gram PRS-343 for HER2+ solid... [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Fo­cused on treat­ments for fi­brot­ic dis­eas­es by har­ness­ing the ther­a­peu­tic po­ten­tial of in­te­grin bi­ol­o­gy and TGF-&be­ta; mo­d­u­la­tion. Lead pro­gram is a small molecule du­al se­lec­tive in­hibi­tor of avb6/avb1... [more in­for­ma­tion]
Poxel SA [POXEL:PA] €129 MM MCap
Safe/more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (mi­to­chon­dria-based MOA) for T2D be­gan Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. Com­ple­tion of Phase 3 on track for 2019 and... [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$200 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs that work by block­ing bi­o­log­i­cal path­ways cur­rent­ly tar­get­ed by mar­ket­ed in­jectable anti­body drugs, and in­jecta­bles... [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$60 MM MCap
Re­com­bi­nant ther­a­peu­tic pro­teins pro­duced us­ing Pro­CellEx®, plant cell-based pro­tein ex­pres­sion sys­tem. Lead as­set, PRX-102, mod­i­fied ver­sion of re­com­bi­nant hu­man al­pha-GAL-A pro­tein, in mul­ti­ple Ph... [more in­for­ma­tion]
PsiOxus Therapeutics
IV ad­min­is­tered T-SIGn on­co virus plat­form trans­forms ade­n­ovirus in­to “armed” vec­tor. The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune... [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$247 MM MCap
A de­vel­op­ment-stage med­i­cal de­vice com­pany us­ing a nov­el and pro­pri­e­tary plat­form tech­nol­o­gy called Nano-Pulse Elec­tro-Sig­nal­ing or NPES. NPES is a lo­cal and drug-free tech­nol­o­gy that uti­l­izes... [more in­for­ma­tion]
Quentis Therapeutics
Pre­clin­i­cal stage biotech­nol­o­gy com­pany trans­lat­ing nov­el bi­ol­o­gy in­to new ther­a­peu­tic ap­proach­es that tar­get path­ways as­so­ci­at­ed with en­do­plas­mic retic­u­lum (ER) stress re­sponse. Lead pro­gram is a... [more in­for­ma­tion]
ReNeuron Group plc [RENE:LN] £16 MM MCap
Clin-stage, UK-based cell ther­a­py; al­lo­gene­ic, off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 de­sign ap­proved by FDA); re­tini­tis pig­men­tosa (Ph1/2 on­go­ing), cone rod dys­tro­phy (Ph2... [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] US$350 MM MCap
Rigel Phar­ma­ceu­ti­cals is ded­i­cat­ed to dis­cov­er­ing, de­vel­op­ing and pro­vid­ing nov­el small molecule drugs for im­mune and he­ma­to­log­ic di­s­or­ders, can­cer and rare dis­eas­es. The com­pany's first FDA ap­proved... [more in­for­ma­tion]
Savara Inc. [SVRA] US$259 MM MCap
Or­phan lung dis­ease co. Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion, and prep for Ph 2a in CF af­fect­ed... [more in­for­ma­tion]
Selvita S.A
Selvi­ta is a $225m Pol­ish on­col­o­gy fo­cused biotech­nol­o­gy com­pany. Broad on­col­o­gy tar­get­ed ther­a­peu­tics pipe­line in­cludes ki­nase in­hibi­tor and syn­thet­ic lethal­i­ty pro­grams. Lead pro­grams in­clude SEL24,... [more in­for­ma­tion]
Sernova [SEOVF] US$25 MM MCap
Ser­no­va Corp. is a clin­i­cal-stage re­gen­er­a­tive medicine com­pany com­mer­cial­iz­ing prod­ucts which ben­e­fit pa­tients with chron­ic metabolic, neu­ro­log­i­cal and he­ma­to­log­i­cal dis­eas­es with first ther­a­peu­tic... [more in­for­ma­tion]
Solebury Capital
Sole­bury Cap­i­tal LLC is a glob­al ad­vi­so­ry firm and reg­is­tered bro­k­er deal­er ex­clu­sive­ly fo­cused on the equi­ty cap­i­tal mar­kets. We pro­vide our cor­po­rate and fi­nan­cial spon­sor clients with in­de­pen­dent... [more in­for­ma­tion]
Solebury Trout
The Trout Group is the lead­ing glob­al in­ves­tor re­la­tions and strate­g­ic ad­vi­so­ry firm ser­vic­ing the life sci­ences in­dus­try. Since 1996, the firm has been pro­vid­ing com­pa­nies with ex­pert counsel and... [more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$324 MM MCap
3 clin­i­cal stage on­col­o­gy prod­uct can­di­dates. 1) EL­ZON­RIS is a tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123) pre­sent on range of ma­lig­nan­cies that suc­cess­ful­ly com­plet­ed a piv­o­tal trial in BPD­CN... [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €664 MM MCap
Au­to­ma­tion sys­tems and soft­ware for di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS (BioMerieux) and AD­VIA... [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$255 MM MCap
Com­mer­cial stage Com­pany fo­cused on rare dis­eas­es with sig­ni­f­i­cant un­met needs. En­docrine franchise in­cludes RE­COR­LEV™, cor­ti­sol syn­th­e­sis in­hibi­tor in Ph 3 studies for en­doge­nous Cush­ing's... [more in­for­ma­tion]
Sutro Biopharma [STRO] US$223 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. The com­pany’s dis­cov­ery and de­vel­op­ment ef­forts are driv­en by... [more in­for­ma­tion]
Lead pneu­mo­coc­cal con­ju­gate vaccine (PCV) ad­dress­es an estab­lished $7B mar­ket op­por­tu­ni­ty and is de­signed to pro­vide ex­pand­ed pro­tec­tion against cir­cu­lat­ing strains of pneu­mo­coc­cus be­yond the cov­er­age... [more in­for­ma­tion]
Taiwan Liposome Company
TLC is a clin­i­cal-stage spe­cial­ty phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to the de­vel­op­ment and com­mer­cial­iza­tion of nov­el nanomedicines that com­bine pro­pri­e­tary lipid-as­sem­bled drug de­liv­ery plat­forms with... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr471 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Tessa Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the treat­ment of can­cer us­ing cell ther­a­py and com­bi­na­tion ap­proach­es. Tes­sa’s Virus-Spe­cif­ic T cell (VST) plat­form redi­rects body’s po­tent... [more in­for­ma­tion]
The Jackson Laboratory
The Jack­son Lab­o­ra­to­ry (pri­vate) is an in­de­pen­dent, 501(c)(3) non­pro­f­it biomed­i­cal re­search in­sti­tu­tion. Found­ed in 1929, The Jack­son Lab­o­ra­to­ry has over 9 de­cades of ex­per­tise in hu­man and mice... [more in­for­ma­tion]
Valbiotis [AVAL-FR]
Plant-de­rived prod­ucts to pre­vent metabolic dis­eas­es. Pipe­line in­cl 5+ prod­ucts tar­get­ing pre­di­a­betes/T2D, NAFL/NASH, dys­lipi­daemia, and obe­si­ty. Lead pro­gram VALE­DIA®, tar­gets un­ad­dressed... [more in­for­ma­tion]
Vericel Corporation [VCEL] US$778 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Epi­cel mar­ket: $2b+. Re­cord 3Q18 rev­enues of $22.5 M rep­re­sents 58% YOY in­crease. FY gui­dance... [more in­for­ma­tion]
Verseon [VSN-LON]
In-house drug dis­cov­ery plat­form, built w 10+ years of R&D. Po­ten­tial­ly first sys­te­m­at­ic, com­pu­ta­tio­n­al­ly-driv­en so­lu­tion to achieve molec­u­lar mod­elling ac­cu­ra­cy ne­ces­sary for rapid /cost-ef­fec­tive... [more in­for­ma­tion]
Veru Inc. [VERU] US$85 MM MCap
Ad­dress­ing pros­tate can­cer and spec phar­ma in urol­o­gy. Zu­clomiphene in Ph 2 treat­ing hot flash­es caused by hor­mone treat­ment for pros­tate can­cer. VERU-111: oral, next-gen, an­ti­tubu­lin agent for... [more in­for­ma­tion]
Viela Bio
Pi­oneer­ing and ad­vanc­ing treat­ments for se­vere in­flam­ma­tion and au­toim­mune dis­eas­es by se­lec­tive­ly tar­get­ing shared crit­i­cal path­ways driv­ing dis­ease patho­ge­n­e­sis. Lead pro­gram, Ine­bi­l­izumab, is a... [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$118 MM MCap
Da­ta-in hand from two Ph. 2 Di­a­betes (T2) trials: 1. Glu­cok­i­nase Ac­ti­va­tor (TT­P399); 2. Oral GLP-1r (TT­P273). Eval­u­at­ing TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in... [more in­for­ma­tion]
Wave Life Sciences Ltd. [WVE] US$1,284 MM MCap
Clin­i­cal-stage, ge­net­ic medicines w chem­istry plat­form en­abling pre­cise de­sign, op­ti­miza­tion and pro­duc­tion of stere­op­ure nu­cle­ic acid ther­a­pies. Top-line da­ta from first 3 clin­i­cal pro­grams, 1 in DMD... [more in­for­ma­tion]
Yisheng Biopharma
Bio­ther­a­peu­tics for can­cers and in­fec­tious dis­ease us­ing PI­KA® im­muno­mo­d­u­lat­ing tech­nol­o­gy; in­flu­enc­ing in­nate and adap­tive im­mune re­spons­es through TL­R3, RIG-I and MDA5 path­ways. Prod­ucts in de­vt... [more in­for­ma­tion]
ZIOPHARM Oncology Inc [ZIOP] US$401 MM MCap
The com­pany is fo­cused on the de­vel­op­ment of two plat­form tech­nolo­gies de­signed to de­liv­er safe, ef­fec­tive and scal­able cell- and vi­ral-based ther­a­pies for the treat­ment of mul­ti­ple can­cer types: (1)... [more in­for­ma­tion]